Distributor inventory | Tablet

Type 2 diabetes mellitus (to improve glycaemic control) as monotherapy or in combination with other antidiabetic medicines along with diet and exercise

Vildagliptin is a DPP-4 inhibitor that increases levels of incretin hormones (GLP-1 and GIP). This enhances glucose-dependent insulin release and reduces glucagon secretion, helping lower blood glucose with a low risk of hypoglycaemia when used alone.

Oral tablet. Take as prescribed by the doctor, usually once or twice daily, with or without food. Swallow whole with water; take at the same time each day and continue diet/exercise plan.

Headache,dizziness,nausea,abdominal pain,diarrhoea,constipation,upper respiratory tract infection,nasopharyngitis,tremor,weakness,peripheral oedema

Not for type 1 diabetes or diabetic ketoacidosis. Monitor liver function before and during treatment; stop and seek medical advice if jaundice, dark urine, persistent nausea/vomiting, or right upper abdominal pain occur (risk of hepatitis). Use with caution in renal impairment; dose adjustment may be required. Rare risk of pancreatitis—seek urgent care for severe persistent abdominal pain. Hypoglycaemia risk increases when combined with sulfonylureas/insulin; dose adjustment may be needed. Caution in heart failure (especially if severe); use only on medical advice. Do not use if allergic to vildagliptin.

Insulin,sulfonylureas (e.g., glimepiride, gliclazide) – increased hypoglycaemia risk,ACE inhibitors – increased risk of angioedema (rare),other antidiabetic medicines (metformin, pioglitazone, SGLT2 inhibitors) – additive glucose lowering

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Galvus 50 Tablet,Zomelis 50 Tablet,Jalra 50 Tablet,Vildagliptin 50 mg Tablet (generic),Vildaglip 50 Tablet